Efficacy analysis of tyrosine kinase inhibitor combinations in phase II clinical trials of non-small cell lung cancer
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
Autor principal: | Flora, Sanzida Alam |
---|---|
Otros Autores: | Azam, Faruque |
Formato: | Tesis |
Lenguaje: | English |
Publicado: |
Brac University
2024
|
Materias: | |
Acceso en línea: | http://hdl.handle.net/10361/23693 |
Ejemplares similares
-
A review on Bruton's Tyrosine Kinase inhibitors to outline the scopes of further advancements in the treatment of cancer
por: Khan, Muidul Hasan
Publicado: (2024) -
Effect of performance status on efficacy endpoints in phase II trials of non-small cell lung cancer
por: Paul, Pulock
Publicado: (2024) -
Impact of treatment size and therapy type in phase II clinical trials of non-small cell lung cancer
por: Rahman, Tasnim
Publicado: (2024) -
A review on cyclin-dependent kinase 7 (CDK7) Inhibitors as anticancer agents
por: Sorno, Rubina Haque
Publicado: (2024) -
Efficacy analysis and prediction in phase II clinical trials of non-small cell Lung Cancer
por: Hoque, Ismoth Ara
Publicado: (2024)